Research advances of antibody-dependent cell-mediated cytotoxicity in the resistance of rituximab
10.3760/cma.j.issn.1009-9921.2013.11.019
- VernacularTitle:抗体依赖细胞介导的细胞毒作用在利妥昔单抗耐药机制中的研究进展
- Author:
Xuan JIN
- Publication Type:Journal Article
- Keywords:
Lymphoma,non-Hodgkin's;
Rituximab;
Resistance mechanism;
Antibody-dependent cell-mediated cytotoxicity
- From:
Journal of Leukemia & Lymphoma
2013;22(11):697-700
- CountryChina
- Language:Chinese
-
Abstract:
Rituximab,a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20,comparing with chemotherapy has significantly improved the treatment outcome of all subgroups of B-cell lymphoma patients.However,not all patients respond to rituximab plus chemotherapy or relapse in a short time after response,which suggests the existence of resistance mechanisms.Antibody-dependent cell-mediated cytotoxicity (ADCC) is one of the main mechanisms of rituximab,so any abnormalities in ADCC pathway may affect the efficacy of rituximab.With the widely application of rituximab,its resistance mechanisms are attracting more attention.This review will summarize the factors within ADCC pathway that may affect the antitumor effect of rituximab.
